Related Experiment Video
Updated: Aug 13, 2025

Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
The FDA modernisation act 2.0: Bringing non-animal technologies to the regulatory table
Alastair Stewart1, Delphine Denoyer1, Xumei Gao1
1ARC Training Centre for Personalised Therapeutics Technologies, Department of Biochemistry and Pharmacology, School of Biomedical Sciences, University of Melbourne, Australia.
Abstract:
The FDA modernisation Act 2.0 marks a game-changing legislation enabling drug registration without the absolute requirement for the use of animals in safety toxicology assessment. We discuss landmark developments in the legislation under which the FDA operates and consider the implications of this most recent chapter in the evolution of the drug regulation pathway, focussing on new opportunities to embed microphysiological systems.
More Related Videos
09:55Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
07:45Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
Related Concept Videos
Drug Regulation
Preclinical Development: Overview
Drug Control Governance: Regulatory Bodies and Their Impact
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...